Cancer reports (Hoboken, N.J.) · 2025
Peripheral Blood CD4/CD8 Ratio Predicts Out-of-Specification Products in Lisocabtagene Maraleucel Manufacturing.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hirano Taichi, Tatetsu Hiro, Ueno Shikiko, Shichijo Takafumi, Nakamura Takahisa, Yamada Asami, Uchiba Mitsuhiro, Kato Koji, Nosaka Kisato, Matsuoka Masao, Yasunaga Jun-Ichirou
Аннотация
BACKGROUND: Lisocabtagene maraleucel (liso-cel) is a CD19-directed chimeric antigen receptor T-cell therapy for patients with relapsed or refractory large B-cell lymphoma.
METHODS: In this retrospective study involving 22 patients, we evaluated the association between peripheral blood CD4/CD8 ratios and the occurrence of out-of-specification (OOS) products during manufacturing. Expanded access protocols have permitted the infusion of OOS products, despite their failure to meet commercial release criteria, under close regulatory oversight.
RESULTS: Five patients who received OOS products had significantly lower CD4/CD8 ratios (median 0.22 vs. 0.46; p = 0.008).
CONCLUSION: Our findings suggest that a low CD4/CD8 ratio (below one-third) may be a predictive marker for OOS outcomes, potentially supporting patient selection and treatment planning. Therefore, prospective validation using a larger cohort is warranted.
METHODS: In this retrospective study involving 22 patients, we evaluated the association between peripheral blood CD4/CD8 ratios and the occurrence of out-of-specification (OOS) products during manufacturing. Expanded access protocols have permitted the infusion of OOS products, despite their failure to meet commercial release criteria, under close regulatory oversight.
RESULTS: Five patients who received OOS products had significantly lower CD4/CD8 ratios (median 0.22 vs. 0.46; p = 0.008).
CONCLUSION: Our findings suggest that a low CD4/CD8 ratio (below one-third) may be a predictive marker for OOS outcomes, potentially supporting patient selection and treatment planning. Therefore, prospective validation using a larger cohort is warranted.